Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Anaptysbio (ANAB) EBITDA (2016 - 2025)

Anaptysbio (ANAB) has disclosed EBITDA for 10 consecutive years, with $49.5 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EBITDA rose 322.79% year-over-year to $49.5 million, compared with a TTM value of -$13.6 million through Dec 2025, up 90.59%, and an annual FY2025 reading of -$13.6 million, up 90.59% over the prior year.
  • EBITDA was $49.5 million for Q4 2025 at Anaptysbio, up from $15.2 million in the prior quarter.
  • Across five years, EBITDA topped out at $49.5 million in Q4 2025 and bottomed at -$46.5 million in Q2 2024.
  • Average EBITDA over 5 years is -$25.4 million, with a median of -$34.8 million recorded in 2022.
  • The sharpest move saw EBITDA plummeted 6778.74% in 2022, then surged 322.79% in 2025.
  • Year by year, EBITDA stood at -$32.8 million in 2021, then increased by 21.7% to -$25.7 million in 2022, then tumbled by 58.5% to -$40.7 million in 2023, then skyrocketed by 45.3% to -$22.2 million in 2024, then soared by 322.79% to $49.5 million in 2025.
  • Business Quant data shows EBITDA for ANAB at $49.5 million in Q4 2025, $15.2 million in Q3 2025, and -$38.8 million in Q2 2025.